Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.4 NOK | +1.59% | +6.67% | +31.69% |
Business Summary
Number of employees: 8
Sales per Business
NOK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oncolytic Peptides
100.0
%
| 17 | 100.0 % | 4 | 100.0 % | -76.89% |
Sales per region
NOK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 11 | 63.9 % | 4 | 100.0 % | -63.82% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Øystein Rekdal
CEO | Chief Executive Officer | - | 02-12-31 |
Gjest Breistein
DFI | Director of Finance/CFO | - | - |
Chief Tech/Sci/R&D Officer | - | 07-12-31 | |
Gry Stensrud
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Ole Peter Nordby
IRC | Investor Relations Contact | - | - |
- | - | ||
Stephen Worsley
PRN | Corporate Officer/Principal | 60 | 22-09-05 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kjetil Hestdal
BRD | Director/Board Member | 64 | 21-06-06 |
Director/Board Member | 66 | 21-06-06 | |
Jayson M. Rieger
BRD | Director/Board Member | 48 | 21-06-06 |
Øystein Rekdal
CEO | Chief Executive Officer | - | 02-12-31 |
Marie Roskrow
CHM | Chairman | - | 23-04-17 |
Evelina Vågesjö
BRD | Director/Board Member | 38 | 21-06-06 |
Director/Board Member | 59 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 50,578,121 | 28,904,723 ( 57.15 %) | 0 | 57.15 % |
Company contact information
Sector
Sales per region
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+31.69% | 30.2M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- LYTIX Stock
- Company Lytix Biopharma